摘要 |
A bispecific antibody specifically binding to the two targets human CD3µ (further named also as "CD3") and the extracellular domain of human ROR1 (further named also as "ROR1"), characterized in that the bispecific antibody does not internalize in a cell based assay at 37°C during 2 hrs., using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, the ” mean fluorescence intensity (”MFI), MFI as measured by flow cytometry, reflecting the internalization (%) of the said antibody to ROR1-positive cells is between 120% to 0%, preferably from 100% to 0%, of the ”MFI (internalization, %) of a defined anti-ROR1 antibody and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or plasma cell disorders like Multiple Myeloma MM or other B-cell disorders expressing ROR1 and ROR1-positive solid tumors. |